Potential Contribution of Preoperative Neoadjuvant Concurrent Chemoradiation Therapy on Margin-Negative Resection in Borderline Resectable Pancreatic Cancer

Journal of Gastrointestinal Surgery

Volumn 16, Issue 3, 2012, Pages 509-517

  Kang, Chang Moo ^a,b,c   Chung, Yong Eun ^a,b,c   Park, Jeong Youp ^a,b,c   Sung, Jin Sil ^a,b   Hwang, Ho Kyoung ^a,b,c   Choi, Hye Jin ^a,b,c   Kim, Hyunki ^a,c   Song, Si Young ^a,b   Lee, Woo Jung ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Young Yonsei Panceatic Tumor Study Group   (South Korea)

Author keywords

Borderline resectable; Chemoradiation; Neoadjuvant; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ADJUVANT THERAPY; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PANCREAS RESECTION; PANCREAS TUMOR; PATHOLOGY; PREOPERATIVE CARE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84856700060     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1784-3     Document Type: Article

References (29)

1. Office. KNS. Annual report on the cause of death statistics-2007. Available form: URL: http://www. nso. go. kr (Korean).
2. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4(6): 567-579.
3. Christein JD, Kendrick ML, Iqbal CW, Nagorney DM, Farnell MB. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005; 9(7): 922-927.
4. Bilimoria KY, Talamonti MS, Sener SF, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 2008; 207(4): 510-519.
5. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U. S.: utilization, outcomes, and the effect of hospital volume. Cancer 2007; 110(6): 1227-1234.
6. Lowy AM. Neoadjuvant therapy for pancreatic cancer. J Gastrointest Surg 2008; 12(9): 1600-1608.
7. Kao PS, Chang SC, Wang LW, et al. The impact of preoperative chemoradiotherapy on advanced low rectal cancer. J Surg Oncol 2010; 102(7): 771-777.
8. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16(7): 1727-1733.
9. National Comprehensive Cancer Network (NCCN). NCCN updates pancreatic adenocarcinoma guidelines. Available at; http://www. nccn. org/professionals/physician_gls/pdf/pancreatic. pdf, accessed February 01 2011.
10. Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; 73(4): 1148-1154.
11. Hong SP, Park JY, Jeon TJ, et al. Weekly full-dose gemcitabine and single-dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2008; 98(5): 881-887.
12. Howard TJ, Krug JE, Yu J, et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006; 10 (10): 1338-1345; discussion 1345-1336.
13. Nagakawa T, Sanada H, Inagaki M, et al. Long-term survivors after resection of carcinoma of the head of the pancreas: significance of histologically curative resection. J Hepatobiliary Pancreat Surg 2004; 11(6): 402-408.
14. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007; 246(1): 52-60.
15. Winter JM, Cameron JL, Campbell KA, et al. 1423 Pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006; 10(9): 1199-1210; discussion 1210-1191.
16. Chun YS, Milestone BN, Watson JC, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol 2010; 17(11): 2832-2838.
17. Springett GM, Hoffe SE. Borderline resectable pancreatic cancer: on the edge of survival. Cancer Control 2008; 15(4): 295-307.
18. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008; 206(5): 833-846; discussion 846-838.
19. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127(11): 1335-1339.
20. Murakami Y, Uemura K, Sudo T, et al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg 2010; 211(2): 196-204.
21. Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009; 13(7): 1337-1344.
22. Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008; 15(1): 165-174.
23. Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011; 18(3): 619-627.
24. Aristu J, Canon R, Pardo F, et al. Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol 2003; 26(1): 30-36.
25. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000; 89(2): 314-327.
26. Pipas JM, Barth RJ, Jr., Zaki B, et al. Docetaxel/gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 2005; 12(12): 995-1004.
27. Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol 2006; 13(9): 1201-1208.
28. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13(8): 1035-1046.
29. Katz MH, Pisters PW, Lee JE, Fleming JB. Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol 2011; 18(3): 608-610.